The federal government’s proposed Agile Licensing drug approval regulations mean Canada will have less information about the risks of new medicines, and higher costs.
Rigor académico, oficio periodístico
Artículos sobre Drug costs
Mostrando todos artículos
New payment models may mean more of the people who need these treatments can get them.
FDA approval of aducanumab (Aduhelm) was contentious. Its submission to Health Canada for approval highlights concerns about evidence, independence and transparency in Canada’s drug approval process.
Studies repeatedly have shown that health care in general and the high cost of drugs in particular are among the top concerns of US voters. But with coronavirus, the issue may fade from prominence.
It’s not the price of health care that should concern us. It’s the cost. There’s a distinction, and it matters. Here’s why.
Support for over-the-counter birth control pills is growing. But a drawback could be that insurers would not pay for them. Also, some people have safety concerns. Could pharmacists be the solution?
CVS, which operates nearly 10,000 pharmacies across the country, announced intentions to buy Aetna, the nation’s third-largest provider of health insurance. Here’s how consumers could be affected.
Have you ever wondered why some drugs are so cheap, and others so expensive? Here’s why.
Principales colaboradores
-
Professor of Health Economics, University of Technology Sydney
-
PhD Candidate in Health Economics, University of Technology Sydney
-
Senior Research Fellow, University of Technology Sydney
-
Joel Lexchin es Amigo de The Conversation.
Professor Emeritus of Health Policy and Management, York University, Canada
-
Associate Professor of Public Health, Texas A&M University
-
Professor of Health Law and Bioethics, Case Western Reserve University
-
Clinical Associate Professor of Pharmacy Practice, Binghamton University, State University of New York
-
Associate Professor of Surgery and Public Policy, University of Virginia
-
Postdoctoral Fellow in Precision Medicine and Emerging Biotechnologies, Arizona State University
-
Professor, School of Population and Public Health, University of British Columbia
-
Director of the Health Law Institute at the Schulich School of Law, Dalhousie University
-
Professor of Economics, University of Calgary
-
Associate professor, School of Public Health, University of Alberta
-
Professor of Health Economics, Queen's University Belfast
